BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease Jan 5, 2021
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD Dec 7, 2020
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference Nov 13, 2020
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Nov 12, 2020
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders Nov 11, 2020
BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting Nov 9, 2020
BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast Nov 5, 2020
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium Oct 26, 2020
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Sep 9, 2020
